Coya Therapeutics' (COYA) "Buy" Rating Reiterated at Chardan Capital

Key Points

• Chardan Capital has reaffirmed a "buy" rating for Coya Therapeutics (NASDAQ:COYA) with a target price of $14.00, suggesting a potential upside of 132.17% from its current trading price.
• Analysts are mixed on COYA, with four maintaining "buy" ratings and one putting a "sell" rating, resulting in a consensus rating of "Moderate Buy" and a target price of $16.50.
• Coya Therapeutics reported a quarterly loss of ($0.36) EPS, significantly missing expectations, and its stock has seen a market capitalization of around $100.88 million as trading volumes remain low.

Chardan Capital reissued their buy rating on shares of Coya Therapeutics (NASDAQ:COYA - Free Report) in a research report report published on Wednesday,Benzinga reports. They currently have a $14.00 price target on the stock.

COYA has been the topic of a number of other reports. D. Boral Capital reiterated a "buy" rating and set a $18.00 target price on shares of Coya Therapeutics in a research report on Thursday, July 24th. HC Wainwright reaffirmed a "buy" rating and set a $18.00 price objective on shares of Coya Therapeutics in a report on Monday, June 9th. Wall Street Zen lowered Coya Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Finally, Lake Street Capital assumed coverage on Coya Therapeutics in a report on Wednesday, July 9th. They issued a "buy" rating and a $16.00 price target on the stock. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $16.50.

Coya Therapeutics Trading Down 2.3%

NASDAQ COYA traded down $0.14 during trading hours on Wednesday, reaching $6.01. 24,599 shares of the company's stock were exchanged, compared to its average volume of 73,576. The firm has a fifty day moving average of $5.97 and a 200-day moving average of $6.09. Coya Therapeutics has a one year low of $4.65 and a one year high of $10.24. The stock has a market cap of $100.55 million, a PE ratio of -4.85 and a beta of 0.26.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.14). The firm had revenue of $0.16 million during the quarter, compared to the consensus estimate of $0.78 million. As a group, research analysts forecast that Coya Therapeutics will post -1.15 EPS for the current year.

Institutional Trading of Coya Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Jane Street Group LLC bought a new position in Coya Therapeutics in the fourth quarter valued at $74,000. Tower Research Capital LLC TRC boosted its stake in shares of Coya Therapeutics by 1,005.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company's stock worth $30,000 after buying an additional 4,777 shares during the last quarter. Northern Trust Corp grew its holdings in shares of Coya Therapeutics by 12.2% in the 4th quarter. Northern Trust Corp now owns 28,549 shares of the company's stock valued at $164,000 after acquiring an additional 3,099 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Coya Therapeutics by 5.8% in the fourth quarter. Geode Capital Management LLC now owns 150,576 shares of the company's stock valued at $863,000 after acquiring an additional 8,267 shares during the last quarter. Finally, DME Capital Management LP boosted its position in Coya Therapeutics by 29.2% during the fourth quarter. DME Capital Management LP now owns 1,646,440 shares of the company's stock valued at $9,434,000 after purchasing an additional 372,414 shares during the last quarter. Institutional investors and hedge funds own 39.75% of the company's stock.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.